Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00935480 | IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients | PHASE3 | COMPLETED | 17 | — | — | Oct 1, 2010 | Aug 8, 2014 | May 12, 2017 | 2 | France |
| Arm | Type | Description |
|---|---|---|
| HAART+Raltegravir 12 months (+/-) Maraviroc | EXPERIMENTAL | - |
| HAART | NO_INTERVENTION | - |
| Name | Type | Description |
|---|---|---|
| Isentress® | DRUG | P.O, 1 tablet containing 400 mg every 12 hours |
| Celsentri® | DRUG | p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA) |
Inclusion Criteria: * Male or female patients, aged over 18 years * HIV infection confirmed by Western Blot * Karnofsky score \> 80% * Treatment-experienced patients having received combined antiretroviral therapy including at least 2 RTI and 1 PI/r for at least 12 months with plasma viral load \<5...